We are pleased to announce that we now accept all major credit cards, as well as HSA and FSA for payment!
Call Us Today!
Click here now
Click here now
Call Us Today!
Click here now
Click here now
Reduced bone density means the bones contain less mineral and may be weaker than expected. It can develop without pain or obvious symptoms, which is why many women do not know they have bone loss until it appears on a bone density test or after a fracture.
Low bone density treatment depends on more than one test result. Age, menopause status, previous fractures, medications, medical conditions, and overall fracture risk all influence the plan. Optimal Female & Men’s Wellness helps women review factors affecting bone health and determine whether nutrition, hormone care, medication management, testing, or referral may be appropriate.
Bone is living tissue that is continually removed and rebuilt. With age, bone breakdown may begin to outpace new bone formation.
Estrogen helps protect bone tissue. As estrogen declines during perimenopause and menopause, bone loss may accelerate. This raises the risk of osteopenia, osteoporosis, and fractures.
Low bone density usually causes no symptoms. Back pain, height loss, or a curved posture may appear only after spinal fractures occur. A fracture from a minor fall may be the first sign of fragile bones.
Risk may rise with a family history of osteoporosis or hip fracture, low body weight, smoking, frequent alcohol use, limited weight-bearing activity, or a previous fracture after minimal trauma.
Thyroid disorders, celiac disease, inflammatory conditions, eating disorders, nutrient malabsorption, long-term corticosteroid use, and some cancer or seizure medications may also contribute. Women with early menopause or surgical removal of the ovaries may need earlier assessment.
A dual-energy X-ray absorptiometry scan, called a DXA or DEXA scan, measures bone mineral density at areas such as the hip and spine.
For postmenopausal women, results are usually reported as a T-score. A T-score between -1.0 and -2.5 is generally described as low bone mass or osteopenia. A score of -2.5 or lower is consistent with osteoporosis.
Premenopausal women are generally assessed with a Z-score, which compares bone density with that of women of a similar age. A low result may prompt evaluation for medication effects or an underlying condition.
A DXA result is only part of the assessment. Fracture history and clinical risk tools may also help estimate the likelihood of a future fracture.
Women age 65 and older are generally advised to receive osteoporosis screening. Younger postmenopausal women may also need screening when risk factors indicate increased fracture risk.
Testing may be considered earlier after a fragility fracture, prolonged corticosteroid use, early menopause, significant height loss, or a medical condition associated with bone loss. The timing of repeat scans depends on the initial result, age, treatment, and risk profile.
Not every woman with osteopenia needs prescription medication. Treatment decisions consider bone density, fracture history, and estimated future fracture risk.
Foundational care includes adequate calcium and vitamin D, weight-bearing activity, resistance training, fall prevention, smoking cessation, and limiting excessive alcohol. Food is generally the preferred calcium source, while supplements may be considered when intake is insufficient.
Strength and balance training can help preserve muscle and reduce falls. Women with osteoporosis or spinal fractures may need guidance before high-impact exercise.
Prescription low bone density treatment may be recommended for women with osteoporosis, certain fragility fractures, or a high calculated fracture risk.
Bisphosphonates are commonly used first-line for postmenopausal women at high risk. Other options may include denosumab, selective estrogen receptor modulators, or medications that stimulate bone formation.
Each option has different benefits, risks, schedules, and monitoring needs. Health history and fracture risk influence the choice, and some medications should not be stopped without a transition plan.
Menopause hormone therapy can help prevent bone loss and reduce fracture risk while it is being used. It may be considered for select women who also have bothersome menopause symptoms and do not have contraindications.
Hormone therapy is not the best low bone density treatment for every woman. Suitability depends on age, menopause timing, blood-clot and cardiovascular risks, liver health, unexplained bleeding, and any history of hormone-sensitive cancer.
Testosterone therapy is not an established treatment for reduced bone density in women and should not be prescribed solely to improve a bone density result.
Reduced bone density often remains silent, but early evaluation can identify risks before a fracture affects mobility and independence.
Schedule an appointment with Optimal Female & Men’s Wellness to discuss menopause-related bone loss, nutrition, medication management, and whether bone density testing or specialist coordination belongs in your care plan.
It means the bones contain less mineral and may have lower strength. It may be described as osteopenia or osteoporosis depending on test results and clinical history.
Usually not. Bone loss is often silent until a fracture occurs. Height loss, back pain, or posture changes may follow spinal fractures.
Osteopenia means bone density is below normal but not within the osteoporosis range. Osteoporosis reflects greater loss and higher fracture risk.
A DXA scan measures bone mineral density, usually at the hip and spine. Results are considered alongside age, fractures, menopause status, and other risks.
The best plan depends on fracture risk and may include nutrition, exercise, fall prevention, medication, menopause care, or treatment of another condition.
No. Some women need monitoring and lifestyle support, while others may need medication because of fractures or high calculated risk.
Yes. Declining estrogen during and after menopause can accelerate bone loss and increase osteoporosis risk.
Menopause hormone therapy can reduce bone loss in selected women, but eligibility must be based on individual benefits and risks.
They support bone health but usually do not replace osteoporosis medication when fracture risk is high. Excessive supplementation may also be harmful.
Women age 65 and older should generally be screened. Younger postmenopausal women may need testing when risk factors increase fracture risk.